RAB17 and ductal breast carcinoma in situ: Taken together, these studies suggest that Rab17 may oppose events that accompany the DCIS to IDC transition – such as the loss of cell polarity and the acquisition of invasiveness – and this is likely to be mediated by controlling endosomal trafficking of pro- and/or anti-invasive receptor cargoes.